Implications of the TPP on the Indian pharma industry might not be entirely clear yet. But there is a need for India to engage in the debate of trade deals and public interest.
Les conséquences des dispositions relatives à la propriété intellectuelle contenues dans l’accord signé entre l’Union Européenne et la Tunisie et leurs conséquences sur la santé publique en Tunisie inquiètent.
So far, the NDA government has been a mute spectator to the US pharma strategy of forcing Indian generics manufacturers to produce only what is required for Indian consumers and abandon the export of cheap drugs to Africa
The United States International Trade Commission (USITC) has published a report on IPR policy transparency by India’s new government
Writing pharmaceutical regulations into international trade deals can have costly consequences.
A quick analysis of the leaked text shows there are good reasons to be concerned that the TPP’s generous IP protections could still prove a minefield for efforts to control drug costs in Canada
Ahead of a meeting between Indian Prime Minister Modi and German Chancellor Merkel this week, European manufacturers had already protested India’s patents policy, arguing that it doesn’t protect sensitive technology.
The TPP’s intellectual property chapter represents nothing less than a disaster for global health. Many harmful provisions still remain in the final chapter, bearing out the concerns of public health advocates.
The TPP could give pharmaceutical corporations more power to control medicine markets and “impose higher prices for longer.”
The lack of access to details in the text means governments can put a positive spin on the deal, but the devil is in the detail.
Australia — along with others such as New Zealand and Chile — has been unwilling to offer more than five years protection for the medicines, because longer terms would increase the cost of state-subsidised medical programs.
Countries in the trade bloc would have an alternative of either providing eight years of exclusivity to biologic drugs, or providing five years of so-called data exclusivity plus up to three more years under a regulatory framework in the TPP.
A standoff between Australia and the United States on monopoly rules for
pharmaceutical drugs has emerged as the ultimate impediment to clinching an
historic trade deal sweeping across 12 Pacific Rim countries.
The latest round of trade talks between Taiwan and the U.S. under the bilateral Trade and Investment Framework Agreement (TIFA) made much ground in a number of areas but both sides have yet to reach consensus on issues such as U.S. pork imports.
The latest round of Trade and Investment Framework Agreement (TIFA) talks with the US ignores the interests of ordinary citizens, labor activists said yesterday.
The talks remained bogged down after two days of negotiations between ministers from the United States, Japan, Australia and nine other countries over a handful of sticky issues.
Les représentants de 12 pays riverains du Pacifique se réunissent à Atlanta pour tenter de parvenir à une entente sur un vaste accord commercial, connu sous son acronyme TPP.
Major challenges in three areas remain in concluding the Trans-Pacific Partnership, according to officials involved in the discussions.
Arrested from hotel demanding to see the secret "death sentence clause"
Despite the deep irony of free trade agreements being subverted to codify and extend anti-competitive monopoly rights the joining of enhanced intellectual property rights (IPRs) and strengthened investor rights is creating a wild-west opportunity for unbounded corporate power.